Influence of Molecular Abnormalities on Treatment Response of Venetoclax Plus Azacytidine and Homoharringtonine Versus Venetoclax Plus Hypomethylating Agent in Relapsed/Refractory Acute Myeloid Leukemia

Yu, Guopan; Yin, Zhao; Jin, Hua; Yu, Sijian; Li, Yuhua; Nie, Danian; Guo, Ziwen; Sun, Zhiqiang; Qian, Meng; Zhao, Wei-Hua; Lin, Dongjun; Xu, Na

doi:10.1182/blood-2022-168004

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The triple combination of VEN, AZA and the histone deacetylase inhibitor tucidinostat in a phase II study yielded a high overall response rate of 75% [112]. Moreover, compared to AZA/VEN in R/R patients, the triplet VEN, AZA and homoharringtonine offered significantly higher rates of CR/CRi (63.8 vs. 40.9%), overall survival (22.1 vs. 16.0 months) and event-free survival (14.3 vs. 2.3 months) with a median follow-up of 14.7 months [113,114]. The promising results of these triplets in R/R AML are worth further exploration in larger studies.…”

Section: Venetoclax-based Approaches For Refractory or Relapsed Amlmentioning

confidence: 97%

Venetoclax Combined with Intensive Chemotherapy: A New Hope for Refractory and/or Relapsed Acute Myeloid Leukemia?

Rahmé,

Braun

2024

JCM

View full text Add to dashboard Cite

Background. Primary resistance of acute myeloid leukemia (AML) to the conventional 3 + 7 intensive chemotherapy and relapses after first-line chemotherapy are two highly challenging clinical scenarios. In these cases, when allogeneic stem cell transplantation is feasible, patients are usually retreated with other chemotherapeutic regimens, as transplantation is still considered, nowadays, the only curative option. Methods. We discuss the mechanisms behind resistance to chemotherapy and offer a comprehensive review on current treatments of refractory/relapsed AML with a focus on novel approaches incorporating the BCL-2 inhibitor venetoclax. Results. Alas, complete remission rates after salvage chemotherapy remain relatively low, between 30 and 60% at best. More recently, the BCL-2 inhibitor venetoclax was combined either with hypomethylating agents or chemotherapy in refractory/relapsed patients. In particular, its combination with chemotherapy offered promising results by achieving higher rates of remission and bridging a substantial number of patients to transplantation. Conclusions. Venetoclax-based approaches might become, in the near future, the new standard of care for refractory/relapsed AML.

show abstract

Section: Venetoclax-based Approaches For Refractory or Relapsed Amlmentioning

confidence: 97%

Venetoclax Combined with Intensive Chemotherapy: A New Hope for Refractory and/or Relapsed Acute Myeloid Leukemia?

Rahmé,

Braun

2024

JCM

View full text Add to dashboard Cite

show abstract

“…Homoharringtonine (HHT), a natural alkaloid derived from the cephalotaxus, is a well-defined anti-AML agent. The triplet of VEN, HMA, and HHT (VAH) [ 8 ] had significantly higher rate of complete remission (CR)/CR with incomplete count recovery (CRi) (63.8% vs. 40.9%, P = 0.003), OS (no reach vs. 16.0 months, P = 0.023) and event-free survival (EFS) (7.1 vs. 2.3 months, P < 0.001) than VEN + HMA group. Subsequently, the data were updated [ 9 ] with a median follow-up of 14.7 months, the median OS was 22.1 months, and EFS was 14.3 months.…”

Section: Ven Combined With Epigenetic Drugs For R/r Amlmentioning

confidence: 99%

Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting

Gong

Zhang

et al. 2023

Exp Hematol Oncol

View full text Add to dashboard Cite

Venetoclax (VEN), the first selective Bcl-2 inhibitor, has shown efficacy and safety both as monotherapy and in combination with other agents in the treatment of newly diagnosed acute myeloid leukemia (AML), while its role in relapsed or refractory (R/R) disease is not well defined. Here, we reviewed the latest advances of VEN-based therapy for R/R AML from the 2022 American Society of Hematology (ASH) Annual Meeting, including some novel and encouraging regimes, such as VCA, VAH, and HAM regimes, etc. Further research is still needed to fully understand the optimal use of these agents in R/R AML treatment.

show abstract

Venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia patients with RUNX1::RUNX1T1: a retrospective propensity score matching study

Wang,

Cao,

Tan

et al. 2023

Blood Cancer J.

View full text Add to dashboard Cite

Influence of Molecular Abnormalities on Treatment Response of Venetoclax Plus Azacytidine and Homoharringtonine Versus Venetoclax Plus Hypomethylating Agent in Relapsed/Refractory Acute Myeloid Leukemia

Cited by 3 publications

References 0 publications

Venetoclax Combined with Intensive Chemotherapy: A New Hope for Refractory and/or Relapsed Acute Myeloid Leukemia?

Venetoclax Combined with Intensive Chemotherapy: A New Hope for Refractory and/or Relapsed Acute Myeloid Leukemia?

Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting

Venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia patients with RUNX1::RUNX1T1: a retrospective propensity score matching study

Contact Info

Product

Resources

About